EMA Application withdrawn: Zemfirza (cediranib maleate) — AstraZeneca AB

View source ↗

Summary

The EMA indicates the Zemfirza (cediranib maleate) application has been withdrawn by AstraZeneca AB for ovarian neoplasms.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Ovarian Neoplasms

Drugs mentioned

• Zemfirza (cediranib maleate)

Snippet

Status: Application withdrawn. Therapeutic area: Ovarian Neoplasms. MAH: AstraZeneca AB. Decision date: 14/10/2016